Novel therapeutic targets and agents for pediatric dyslipidemia

Landmark studies have convincingly demonstrated that atherosclerosis begins in youth. While generally asymptomatic, an increasing number of youth with disorders of lipid and lipoprotein metabolism, such as familial hypercholesterolemia, are being identified through selective and universal screening....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bhuvana Sunil, Christy Foster, Don P. Wilson, Ambika P. Ashraf
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/2e65083e79b2421a91972ca99f34a5a3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2e65083e79b2421a91972ca99f34a5a3
record_format	dspace
spelling	oai:doaj.org-article:2e65083e79b2421a91972ca99f34a5a32021-12-01T00:05:45ZNovel therapeutic targets and agents for pediatric dyslipidemia2042-019610.1177/20420188211058323https://doaj.org/article/2e65083e79b2421a91972ca99f34a5a32021-11-01T00:00:00Zhttps://doi.org/10.1177/20420188211058323https://doaj.org/toc/2042-0196Landmark studies have convincingly demonstrated that atherosclerosis begins in youth. While generally asymptomatic, an increasing number of youth with disorders of lipid and lipoprotein metabolism, such as familial hypercholesterolemia, are being identified through selective and universal screening. While a heart healthy lifestyle is the foundation of treatment for all youth with dyslipidemia, lipid-lowering therapy may be required by some to prevent morbidity and premature mortality, especially when initiated at a young age. When appropriate, use of statins has become standard of care for reducing low-density lipoprotein cholesterol, while fibrates may be beneficial in helping to lower triglycerides. Many therapeutic options commonly used in adults are not yet approved for use in youth less than 18 years of age. Although currently available lipid-lowering therapy is well tolerated and safe when administered to youth, response to treatment may vary and some conditions lack an efficient therapeutic option. Thus, newer agents are needed to aid in management. Many are in development and clinical trials in youth are currently in progress but will require FDA approval before becoming commercially available. Many utilize novel approaches to favorably alter lipid and lipoprotein metabolism. In the absence of long-term outcome data of youth who were treated beginning at an early age, clinical registries may prove to be useful in monitoring safety and efficacy and help to inform clinical decision-making. In this manuscript, we review currently available and novel therapeutic agents in development for the treatment of elevated cholesterol and triglycerides.Bhuvana SunilChristy FosterDon P. WilsonAmbika P. AshrafSAGE PublishingarticleDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENTherapeutic Advances in Endocrinology and Metabolism, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	Diseases of the endocrine glands. Clinical endocrinology RC648-665 Bhuvana Sunil Christy Foster Don P. Wilson Ambika P. Ashraf Novel therapeutic targets and agents for pediatric dyslipidemia
description	Landmark studies have convincingly demonstrated that atherosclerosis begins in youth. While generally asymptomatic, an increasing number of youth with disorders of lipid and lipoprotein metabolism, such as familial hypercholesterolemia, are being identified through selective and universal screening. While a heart healthy lifestyle is the foundation of treatment for all youth with dyslipidemia, lipid-lowering therapy may be required by some to prevent morbidity and premature mortality, especially when initiated at a young age. When appropriate, use of statins has become standard of care for reducing low-density lipoprotein cholesterol, while fibrates may be beneficial in helping to lower triglycerides. Many therapeutic options commonly used in adults are not yet approved for use in youth less than 18 years of age. Although currently available lipid-lowering therapy is well tolerated and safe when administered to youth, response to treatment may vary and some conditions lack an efficient therapeutic option. Thus, newer agents are needed to aid in management. Many are in development and clinical trials in youth are currently in progress but will require FDA approval before becoming commercially available. Many utilize novel approaches to favorably alter lipid and lipoprotein metabolism. In the absence of long-term outcome data of youth who were treated beginning at an early age, clinical registries may prove to be useful in monitoring safety and efficacy and help to inform clinical decision-making. In this manuscript, we review currently available and novel therapeutic agents in development for the treatment of elevated cholesterol and triglycerides.
format	article
author	Bhuvana Sunil Christy Foster Don P. Wilson Ambika P. Ashraf
author_facet	Bhuvana Sunil Christy Foster Don P. Wilson Ambika P. Ashraf
author_sort	Bhuvana Sunil
title	Novel therapeutic targets and agents for pediatric dyslipidemia
title_short	Novel therapeutic targets and agents for pediatric dyslipidemia
title_full	Novel therapeutic targets and agents for pediatric dyslipidemia
title_fullStr	Novel therapeutic targets and agents for pediatric dyslipidemia
title_full_unstemmed	Novel therapeutic targets and agents for pediatric dyslipidemia
title_sort	novel therapeutic targets and agents for pediatric dyslipidemia
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/2e65083e79b2421a91972ca99f34a5a3
work_keys_str_mv	AT bhuvanasunil noveltherapeutictargetsandagentsforpediatricdyslipidemia AT christyfoster noveltherapeutictargetsandagentsforpediatricdyslipidemia AT donpwilson noveltherapeutictargetsandagentsforpediatricdyslipidemia AT ambikapashraf noveltherapeutictargetsandagentsforpediatricdyslipidemia
_version_	1718406130522128384

Novel therapeutic targets and agents for pediatric dyslipidemia

Ejemplares similares